Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1102 clinical trials
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.

measurable disease
ejection fraction
solid neoplasm
  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

lung cancer
cancer treatment
cancer
hair thinning
cancer therapy
  • 0 views
  • 19 Feb, 2024
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions

The main purpose of this study is to evaluate the efficacy and safety of nicotinic acid in solid tumor patients with grade II/III VEGFRi-associated HFSR.

  • 0 views
  • 19 Feb, 2024
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors. The study is divided into …

solid tumour
lymphoma
solid tumor
non-small cell lung cancer
measurable disease
  • 0 views
  • 19 Feb, 2024
SBRT for Breast Cancer Oligometastases

Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria.

breast neoplasm malignant female
breast cancer
cancer
bone scan
primary tumor
  • 0 views
  • 19 Feb, 2024
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

hiv related lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
gemox
lymphoma
  • 0 views
  • 19 Feb, 2024
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

pancreatic neuroendocrine tumor
thymic carcinoma
solid tumour
neuroendocrine carcinoma
transitional cell carcinoma
  • 0 views
  • 19 Feb, 2024
PSMA-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

cancer chemotherapy
platelet count
immunosuppressive agents
pdac
gemcitabine
  • 0 views
  • 19 Feb, 2024
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy

measurable disease
blood pregnancy test
cancer
  • 0 views
  • 19 Feb, 2024